Benazeprilat (Synonyms: CGS 14831)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Benazeprilat  (Synonyms: CGS 14831) 纯度: ≥99.0%

Benazeprilat 是一种具有口服活性的贝那普利活性代谢物，贝那普利是一种具有抗高血压活性的含羧基血管紧张素转换酶 ACE 抑制剂。Benazeprilat 是一种公认的抗高血压剂，无论是单药研究还是与其他类别的药物（包括噻嗪类利尿剂和钙通道阻滞剂）联合使用。Benazeprilat 是减少与心血管风险和继发性终末器官损伤相关的各种病理的一线研究药物。

Benazeprilat (Synonyms: CGS 14831)

Benazeprilat Chemical Structure

CAS No. : 86541-78-8

规格 价格 是否有货 数量
1 mg ￥1864 In-stock
5 mg ￥4100 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Benazeprilat 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Drug Repurposing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Alkaloids Library
  • Angiogenesis-Related Compound Library
  • Drug Metabolite Library
  • Human Metabolite Library
  • Off-patent Drug Library
  • Antihypertensive Compound Library
  • Protease Inhibitor Library
  • Membrane Protein-targeted Compound Library

•同靶点产品:

•同靶点蛋白产品:

生物活性

Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage[1][2][3].

体内研究
(In Vivo)

Benazeprilat (10 mg/kg, intravenous injection) and amlodipine (0.5 mg/kg, intravenous injection) in combination produce great hypotensive effect[2].
Benazepril (0.7 mg/kg, oral) markedly influences the dynamics of systemic RAAS peptides, resulting in a substantial decrease in AII and ALD while increasing PRA and AI[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male SHR (14-16 weeks of age, 250-350 g)[2].
Dosage: 10 mg/kg
Administration: I.V; once a day for 2 days.
Result: Produced hypotensive effect.
Animal Model: Beagle dogs (12.0-19.5 kg)[3].
Dosage: 0.7 mg/kg
Administration: P.O, once a day for 5 days.
Result: Effected systemic RAAS peptides.

分子量

396.44

Formula

C22H24N2O5
CAS 号

86541-78-8
性状

固体

颜色

White to off-white

中文名称

贝那普利EP杂质C
结构分类
  • Alkaloids
  • Other Alkaloids
初始来源
  • 内源性代谢物
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
纯度 & 产品资料

纯度: ≥99.0%

Data Sheet (543 KB) SDS (393 KB)

COA (203 KB)

产品使用指南 (1538 KB)

参考文献

  • [1]. Barrios V, Antihypertensive and organ-protective effects of benazepril. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1653-71.  [Content Brief]

    [2]. Bazil MK, Hemodynamic effects of amlodipine and benazeprilat in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993 Mar;21(3):405-11.  [Content Brief]

    [3]. Mochel JP, Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. J Vet Pharmacol Ther. 2013 Apr;36(2):174-80.  [Content Brief]

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务